The Fen-Phen finale: A study of weight loss and valvular heart disease

Obesity Research

Volumn 6, Issue 4, 1998, Pages 278-284

  Wadden, Thomas A ^a   Berkowitz, Robert I ^a   Silvestry, Frank ^a   Vogt, Renee A ^a   St John Sutton, Martin G ^a   Stunkard, Albert J ^a   Foster, Gary D ^a   Aber, Jennifer L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fenfluramine; Obesity; Phentermine; Valvular heart disease; Weight loss

Indexed keywords

FENFLURAMINE; LIPID; PHENTERMINE;

ADULT; AFFECT; APPETITE; ARTICLE; BEHAVIOR THERAPY; BLOOD; CHEMICALLY INDUCED DISORDER; DOPPLER ECHOCARDIOGRAPHY; DRUG COMBINATION; ECHOGRAPHY; FEMALE; HUMAN; MIDDLE AGED; OBESITY; PREVALENCE; PSYCHOLOGICAL ASPECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ADULT; AFFECT; APPETITE; BEHAVIOR THERAPY; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; LIPIDS; MIDDLE AGED; OBESITY; PHENTERMINE; PREVALENCE; WEIGHT LOSS;

EID: 0032113525     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1998.tb00350.x     Document Type: Article

References (8)

1. U.S. Department of Health and Human Services, HHS News. PDA Announces Withdrawal of Fenfluramine and Dexfenfliiramine. Rockville, MD: 1997.
2. Wyeth-Ayerst Laboratories. Pondimin and Redux to Be Voluntarily Withdrawn (letter to health care providers). Philadelphia, PA: 1997.
3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
4. Bowen R, Glicklich A, Kahn M, et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR. 1997; 46:1061-6.
5. Kassirer JP, Angell M. Losing weight-an ill-fated New Year's resolution. N Engl J Med. 1998;338:52-4.
6. Wadden TA, Berkowitz RI, Vogt RA, Steen SN, Stunkard AJ, Foster GD. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res. 1997;5:218-26.
7. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993;119:707-13.
8. Goldstein D, Potvin J. Long-term weight loss: the effects of pharmacologie agents. Am J Clin Nutr. 1994;60:647-57.